A Mab A Case Study In Bioprocess Development [upd] Jun 2026

A Mab A Case Study In Bioprocess Development [upd] Jun 2026

It outlines a systematic approach to identifying which product attributes (like glycosylation or aggregation) significantly impact safety and efficacy. Upstream Manufacturing Development:

Out of 500 clones screened, Clone 17B shows the highest specific productivity (qP = 25 pg/cell/day). However, early batch cultures reveal a problematic metabolite profile: high lactate accumulation (4 g/L) and ammonia (2 mM). High lactate inhibits cell growth and reduces final titers.

Commercially available ELISA kits quantified residual HCP (

The depth filters for the Protein A load are undersized by linear scale-up (based on volume). A more accurate scale-up factor——shows that the large-scale filter needs 2.5x more area than calculated. After revision, all filter capacity tests pass.

Fine depth filter to remove sub-micron particles and colloidal matter.

It outlines a systematic approach to identifying which product attributes (like glycosylation or aggregation) significantly impact safety and efficacy. Upstream Manufacturing Development:

Out of 500 clones screened, Clone 17B shows the highest specific productivity (qP = 25 pg/cell/day). However, early batch cultures reveal a problematic metabolite profile: high lactate accumulation (4 g/L) and ammonia (2 mM). High lactate inhibits cell growth and reduces final titers. A Mab A Case Study In Bioprocess Development

Commercially available ELISA kits quantified residual HCP ( It outlines a systematic approach to identifying which

The depth filters for the Protein A load are undersized by linear scale-up (based on volume). A more accurate scale-up factor——shows that the large-scale filter needs 2.5x more area than calculated. After revision, all filter capacity tests pass. High lactate inhibits cell growth and reduces final titers

Fine depth filter to remove sub-micron particles and colloidal matter.